<p>医疗器械公司 <strong>Autonomix Medical</strong>（纳斯达克股票代码：<strong>AMIX</strong>）周一突然引起交易者的关注，在波动交易中达到了 150% 的高点。一项与 <strong>RF Innovations</strong> 达成的许可协议的公告推动了市场情绪。这则消息为 AMIX 股票树立了可靠性，因为该公司正在开发与外周神经系统相关疾病的解决方案。</p>
<p>根据随附的新闻稿，该协议的重点是 Apex 6 Generator，这是一项疼痛管理技术。该协议使 Autonomix 获得了 Apex 6 Generator 知识产权的 “永久非独占性全球和免版税许可”。另一方面，Autonomix 将向 RF 发行 25 万股 AMIX 股票。</p>
<p>根据新闻稿，Autonomix 打算利用这项技术在其战略治疗单元中增加价值。总裁兼首席执行官 Brad Hauser 表示：“这项交易代表了我们创新技术平台发展和商业化的重要一步，有可能简化我们的监管策略，因为 Apex 6 Generator 在疼痛管理方面已经获得 FDA 批准。”</p>
<p>最终，这项交易可能有助于阐明与神经系统相关的疾病，并改善这类疾病的诊断和治疗。</p>
<h2>AMIX 股票可能受益于不断壮大的生态系统</h2>
<p>关于 AMIX 股票的另一个要考虑的因素是更广泛的疼痛管理市场。就国内药品行业而言，该生态系统在 2022 年价值 299.9 亿美元。Precedence Research 的专家认为，到 2032 年，该市场规模可能扩大到 417.2 亿美元，暗示了年复合增长率为 3.4%。</p>
<p>更具体地，Grand View Research 指出，全球疼痛管理器械市场在 2022 年价值 69.2 亿美元。分析师预计，从 2023 年到 2030 年，该领域的增长率将达到 9.5%。在最终阶段，市场规模可能达到 141.4 亿美元。考虑到 AMIX 股票的市值略高于 2800 万美元，理论上还有相当大的增长空间。</p>
<p>与此同时，Autonomix 是一家投机性企业。该公司于今年 1 月底在公开市场上市。即使在今天的剧烈上涨中，AMIX 股票的表现仍落后约 70%。值得注意的是，Autonomix 是一家无收入的实体。因此，这是一种高度投机的投资，没有分析师覆盖。</p>
<p>_<strong>关于低价股和低交易量股票：</strong> 除了极少数例外情况外，InvestorPlace 不会发表关于市值低于 1 亿美元或每天交易量低于 10 万股的公司的评论。这是因为这些 “低价股” 经常成为骗子和市场操纵者的活动场所。如果我们确实发表了可能受到我们评论影响的低交易量股票的评论，我们要求 InvestorPlace.com 的撰稿人披露这一事实，并警告读者注意风险。</p>
<p><em><strong>阅读更多：</strong> 低价股 —</em> <em>如何获利而不受骗</em></p>
<p><em>在本文发布日期，Josh Enomoto 对本文提及的证券没有（直接或间接）任何持仓。本文中表达的观点属于作者个人，遵守 InvestorPlace.com</em> <em>发布准则</em>。</p>
<p>_在本文发布日期，负责编辑对本文提及的证券没有（直接或间接）任何持仓。</p>
<p>Josh Enomoto 曾是索尼电子的高级业务分析师，曾帮助与财富全球 500 强公司达成重要合同。在过去几年中，他为投资市场以及法律、建筑管理和医疗保健等其他行业提供了独特而关键的见解。在 Twitter 上关注他 @EnomotoMedia。</p>
<p>生物技术，医疗保健</p>
<p>低价股</p>

AMIX

顶点软件

<p>Autonomix Medical（纳斯达克股票代码：AMIX）宣布与 RF Innovations 签订许可协议后，股价暴涨 120%。该协议授予 Autonomix 永久的非独占性全球免版税许可，涵盖了 Apex 6 Generator 的知识产权。作为交换，Autonomix 将向 RF 发行 25 万股 AMIX 股票。这项交易有望提升 Autonomix 的价值并简化其监管策略。更广泛的疼痛管理市场也为 AMIX 股票提供增长机会</p>

<p>Medical device firm <strong>Autonomix Medical</strong> (NASDAQ: <strong>AMIX</strong>) popped into traders’ radar on Monday, peaking at 150% before engaging in choppy trading. An announcement of a licensing agreement with <strong>RF Innovations</strong>, a privately held medical technology specialist, catapulted sentiment. The news established credibility for AMIX stock as the underlying enterprise moves to develop solutions for disorders related to the peripheral nervous system.</p>
<div class="lb-trans"><p>医疗器械公司 <strong>Autonomix Medical</strong>（纳斯达克股票代码：<strong>AMIX</strong>）周一突然引起交易者的关注，在波动交易中达到了 150% 的高点。一项与 <strong>RF Innovations</strong> 达成的许可协议的公告推动了市场情绪。这则消息为 AMIX 股票树立了可靠性，因为该公司正在开发与外周神经系统相关疾病的解决方案。</p>
</div><p>According to the accompanying press release, the agreement centers on the Apex 6 Generator, which is a pain management technology. The deal enables Autonomix a “perpetual non-exclusive worldwide and royalty-free license of the Apex 6 Generator intellectual property.” On the other end, Autonomix will issue RF 250,000 shares of AMIX stock.</p>
<div class="lb-trans"><p>根据随附的新闻稿，该协议的重点是 Apex 6 Generator，这是一项疼痛管理技术。该协议使 Autonomix 获得了 Apex 6 Generator 知识产权的 “永久非独占性全球和免版税许可”。另一方面，Autonomix 将向 RF 发行 25 万股 AMIX 股票。</p>
</div><p>Per the release, Autonomix intends to leverage the technology in its strategic therapeutic units to enhance value for its pipeline. “This transaction represents a significant step forward for the development and commercialization of our innovative technology platform and can potentially simplify our regulatory strategy, as the Apex 6 Generator is already FDA-cleared in pain management,” stated President and CEO Brad Hauser.</p>
<div class="lb-trans"><p>根据新闻稿，Autonomix 打算利用这项技术在其战略治疗单元中增加价值。总裁兼首席执行官 Brad Hauser 表示：“这项交易代表了我们创新技术平台发展和商业化的重要一步，有可能简化我们的监管策略，因为 Apex 6 Generator 在疼痛管理方面已经获得 FDA 批准。”</p>
</div><p>Ultimately, the deal may help illuminate nervous-system-related diseases and improve how such conditions are diagnosed and treated.</p>
<div class="lb-trans"><p>最终，这项交易可能有助于阐明与神经系统相关的疾病，并改善这类疾病的诊断和治疗。</p>
</div><h2>AMIX Stock May Benefit From a Burgeoning Ecosystem</h2>
<div class="lb-trans"><h2>AMIX 股票可能受益于不断壮大的生态系统</h2>
</div><p>Another factor to consider regarding AMIX stock is the broader pain management market. In terms of the domestic drugs sector, the ecosystem was worth $29.99 billion in 2022. Experts at Precedence Research believe that it could expand to $41.72 billion by 2032, implying a compound annual growth rate of 3.4%.</p>
<div class="lb-trans"><p>关于 AMIX 股票的另一个要考虑的因素是更广泛的疼痛管理市场。就国内药品行业而言，该生态系统在 2022 年价值 299.9 亿美元。Precedence Research 的专家认为，到 2032 年，该市场规模可能扩大到 417.2 亿美元，暗示了年复合增长率为 3.4%。</p>
</div><p>More specifically, Grand View Research notes that the global pain management device market was worth $6.92 billion in 2022. Analysts anticipate that from 2023 to 2030, the segment will expand at a CAGR of 9.5%. At the culmination point, the market could be valued at $14.14 billion. With AMIX stock carrying a market capitalization of a little over $28 million, there’s theoretically significant room to run.</p>
<div class="lb-trans"><p>更具体地，Grand View Research 指出，全球疼痛管理器械市场在 2022 年价值 69.2 亿美元。分析师预计，从 2023 年到 2030 年，该领域的增长率将达到 9.5%。在最终阶段，市场规模可能达到 141.4 亿美元。考虑到 AMIX 股票的市值略高于 2800 万美元，理论上还有相当大的增长空间。</p>
</div><p>At the same time, Autonomix is a speculative enterprise. The company made its public market debut in late January of this year. Even with today’s dramatic surge, AMIX stock is off the pace by around 70%. It’s also worth noting that Autonomix is a pre-revenue entity. Therefore, it’s a highly speculative play without analyst coverage.</p>
<div class="lb-trans"><p>与此同时，Autonomix 是一家投机性企业。该公司于今年 1 月底在公开市场上市。即使在今天的剧烈上涨中，AMIX 股票的表现仍落后约 70%。值得注意的是，Autonomix 是一家无收入的实体。因此，这是一种高度投机的投资，没有分析师覆盖。</p>
</div><p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong> With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.</em></p>
<div class="lb-trans"><p>_<strong>关于低价股和低交易量股票：</strong> 除了极少数例外情况外，InvestorPlace 不会发表关于市值低于 1 亿美元或每天交易量低于 10 万股的公司的评论。这是因为这些 “低价股” 经常成为骗子和市场操纵者的活动场所。如果我们确实发表了可能受到我们评论影响的低交易量股票的评论，我们要求 InvestorPlace.com 的撰稿人披露这一事实，并警告读者注意风险。</p>
</div><p><em><strong>Read More:</strong> Penny Stocks —</em> <em>How to Profit Without Getting Scammed</em></p>
<div class="lb-trans"><p><em><strong>阅读更多：</strong> 低价股 —</em> <em>如何获利而不受骗</em></p>
</div><p><em>On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p><em>在本文发布日期，Josh Enomoto 对本文提及的证券没有（直接或间接）任何持仓。本文中表达的观点属于作者个人，遵守 InvestorPlace.com</em> <em>发布准则</em>。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在本文发布日期，负责编辑对本文提及的证券没有（直接或间接）任何持仓。</p>
</div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p>
<div class="lb-trans"><p>Josh Enomoto 曾是索尼电子的高级业务分析师，曾帮助与财富全球 500 强公司达成重要合同。在过去几年中，他为投资市场以及法律、建筑管理和医疗保健等其他行业提供了独特而关键的见解。在 Twitter 上关注他 @EnomotoMedia。</p>
</div><p>Biotech, Healthcare</p>
<div class="lb-trans"><p>生物技术，医疗保健</p>
</div><p>Penny Stocks</p>
<div class="lb-trans"><p>低价股</p>
</div>

为什么 Autonomix Medical (AMIX) 的股票今天上涨了 120%？